forager
发表于 2025-3-27 00:46:49
http://reply.papertrans.cn/43/4209/420894/420894_31.png
纠缠
发表于 2025-3-27 01:15:46
Exploitation in Biomedical Research the obligations of non-exploitation held by researchers, sponsors, and third parties such as ethics committees and regulators are outlined. The chapter ends by considering how exploitative research in the past can be retroactively remediated.
hemorrhage
发表于 2025-3-27 05:26:26
http://reply.papertrans.cn/43/4209/420894/420894_33.png
N防腐剂
发表于 2025-3-27 10:06:43
http://reply.papertrans.cn/43/4209/420894/420894_34.png
Individual
发表于 2025-3-27 15:29:34
http://reply.papertrans.cn/43/4209/420894/420894_35.png
PURG
发表于 2025-3-27 17:46:22
http://reply.papertrans.cn/43/4209/420894/420894_36.png
CROAK
发表于 2025-3-28 01:12:52
http://reply.papertrans.cn/43/4209/420894/420894_37.png
责怪
发表于 2025-3-28 05:59:26
Book 2023ble resource for professionals working on different bioethical and biomedical fields, such as, ethics and bioethics committees, health care institutions, biomedical and pharmacological companies, and academic settings, among others..Chapter 26 is available open access under a Creative Commons Attrib
阻止
发表于 2025-3-28 06:19:40
Introduction: Scientific Integrity and Institutional Ethics: Challenges and Perspectives,of acute decision-making problems in institutional ethics atmospheres is increasingly profuse. Such dilemmas have become progressively complex as controversy of biomedical and clinical practices boosts. For this reason, the relevance of crucial decisions made in the institutional ethics field demand
generic
发表于 2025-3-28 12:09:45
Confidentiality and Privacy in Digital Clinical Trials purposes. This modality offers numerous advantages both to researchers, sponsors, patients themselves and the rest of actors involved in studies. However, there are also multiple challenges that must be addressed from technical, legal and bioethical perspectives.